Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Metrics to compare | DAWN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDAWNPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.3x | −1.2x | −0.6x | |
PEG Ratio | −0.16 | −0.05 | 0.00 | |
Price/Book | 1.7x | 1.7x | 2.6x | |
Price / LTM Sales | 4.2x | 8.2x | 3.3x | |
Upside (Analyst Target) | 229.4% | 278.7% | 38.7% | |
Fair Value Upside | Unlock | 28.0% | 5.1% | Unlock |